Genfit S.A. (GNFTF)
USD 5.55
(0.0%)
USD 5.55
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -7.6 Million EUR | 88.3% |
| 2022 | -65 Million USD | 69.01% |
| 2021 | -209.75 Million USD | -1269.37% |
| 2020 | 17.93 Million USD | 117.16% |
| 2019 | -104.53 Million USD | -205.52% |
| 2018 | 99.06 Million USD | 176.63% |
| 2017 | 35.81 Million USD | 123.25% |
| 2016 | -154.02 Million USD | -160.59% |
| 2015 | -59.1 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 1.78 Million USD | 0.0% |
| 2023 Q2 | -39.71 Million USD | 2.12% |
| 2023 Q3 | -9.18 Million USD | 76.88% |
| 2023 Q4 | -7.6 Million EUR | 17.15% |
| 2023 Q1 | -40.57 Million USD | 37.58% |
| 2023 FY | -7.6 Million EUR | 88.3% |
| 2022 Q2 | -140.85 Million USD | 0.0% |
| 2022 FY | -65 Million USD | 69.01% |
| 2022 Q3 | -60.51 Million USD | 57.04% |
| 2022 Q4 | -65 Million USD | -7.42% |
| 2021 Q2 | -39.66 Million USD | 0.0% |
| 2021 FY | -209.75 Million USD | -1269.37% |
| 2021 Q4 | -209.75 Million USD | 0.0% |
| 2020 Q2 | -46.14 Million USD | 0.0% |
| 2020 FY | 17.93 Million USD | 117.16% |
| 2020 Q4 | 17.93 Million USD | 0.0% |
| 2019 Q4 | -104.53 Million USD | 0.0% |
| 2019 FY | -104.53 Million USD | -205.52% |
| 2019 Q2 | -113.75 Million USD | 0.0% |
| 2018 FY | 99.06 Million USD | 176.63% |
| 2017 FY | 35.81 Million USD | 123.25% |
| 2016 FY | -154.02 Million USD | -160.59% |
| 2015 FY | -59.1 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 148.271% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 284.773% |
| SQZ Biotechnologies Company | -36.23 Million USD | 79.003% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 117.781% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | -20.691% |
| Mesoblast Limited | 55.85 Million USD | 113.622% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 920.655% |
| Genus plc | 190.6 Million USD | 103.992% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 440.321% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 726.829% |
| Marizyme, Inc. | 18.56 Million USD | 140.977% |
| ContraFect Corporation | -6.02 Million USD | -26.269% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 1218.971% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 5751.409% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 758.543% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 439.349% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 238.298% |
| MultiCell Technologies, Inc. | 90.04 USD | 8450788.583% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -936.68% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 158.775% |
| EV Biologics, Inc. | 1.36 Million USD | 656.225% |
| Q BioMed Inc. | 4.06 Million USD | 287.413% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 124.903% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 1322.596% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 855.074% |
| Biomind Labs Inc. | 711.4 Thousand USD | 1169.578% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 109.8 Million USD | 106.93% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 159.415% |
| Skye Bioscience, Inc. | -5.72 Million USD | -32.992% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 984.52% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 5542.62% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 234.711% |
| IMV Inc. | 7.67 Million USD | 199.198% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 38399.693% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 445.552% |
| GB Sciences, Inc. | 1.74 Million USD | 535.468% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -4040.096% |
| HST Global, Inc. | 96.79 Thousand USD | 7961.106% |
| CSL Limited | 10.52 Billion USD | 100.072% |
| Halberd Corporation | 144.72 Thousand USD | 5357.703% |
| Enzolytics Inc. | 981.65 Thousand USD | 875.119% |
| Resverlogix Corp. | 6.45 Million USD | 217.951% |
| Affymax, Inc. | -5.59 Million USD | -35.948% |
| SYBLEU INC | 473.71 Thousand USD | 1706.243% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -1030.46% |
| argenx SE | -2.02 Billion USD | 99.625% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 117.519% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 83.815% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 380.918% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 13.924% |
| AVAX Technologies, Inc. | -5.9 Million USD | -28.896% |
| Zenith Capital Corp. | 10.06 Thousand USD | 75706.121% |
| Genscript Biotech Corporation | -1.06 Billion USD | 99.283% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 3896.3% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 418.897% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 4725.279% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 112.567% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 480.566% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -2.57 Million USD | -196.066% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 2215.315% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 137.527% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -41438.378% |
| BioStem Technologies, Inc. | 4.47 Million USD | 270.147% |
| ONE Bio Corp. | 9.04 Million USD | 184.17% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 3880.794% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -580739.695% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 3789.802% |
| Agentix Corp. | 37.63 Thousand USD | 20320.031% |
| LadRx Corporation | -2.03 Million USD | -273.637% |
| Cell Source, Inc. | 9.23 Million USD | 182.42% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -37184.398% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 1297.953% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 1297.953% |
| NovAccess Global Inc. | 2.17 Million USD | 449.283% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 207.609% |
| Itoco Inc. | 228.3 Thousand USD | 3432.822% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 5695.306% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 253.5% |
| Kadimastem Ltd | -253.1 Thousand USD | -2906.298% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 1993.497% |
| CytoDyn Inc. | 20.26 Million USD | 137.553% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -1175943.277% |
| Mobile Lads Corp. | 484.23 Thousand USD | 1671.354% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -81996.686% |
| Qrons Inc. | 351.42 Thousand USD | 2265.172% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 198.741% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -2948.233% |
| Rebus Holdings, Inc. | 305 Thousand USD | 2594.754% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 270.719% |
| International Stem Cell Corporation | 2.59 Million USD | 393.784% |
| Bioxytran, Inc. | 1.89 Million USD | 500.703% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 12291.37% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 448.893% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 321.578% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 188.963% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 1084.847% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -508.72% |
| Neutra Corp. | 52.18 Thousand USD | 14680.259% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -205.705% |
| PureTech Health plc | -167.19 Million USD | 95.449% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -3006.881% |
| IXICO plc | -4.44 Million USD | -71.197% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 157.561% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 113.872% |
| CSL Limited | 10.52 Billion USD | 100.072% |
| Cellectis S.A. | -43.81 Million USD | 82.635% |